Mar. 13 at 5:59 PM
$LRMR What a crazy opportunity to buy stock in this company at this level thanks to the war in Iran. Considering the priority review vouchers upon approval, plus huge cash reverses, plus strong data so far, Breakthrough Therapy Designation, this is a no brainer. First in class treatment replacing the current standard of care and shifting the treatment paradigm of a drug bought initially for 7 billion dolars. When they report Top Line data in Q2 it will surge significantly. Whoever is not affraid to accumulate here, should be rewarded later on in less than 2 months
